DE2300322A1 - 5-hydroxy-2-(3-trifluormethylanilino)pyridin-3-carbonsaeure, verfahren zu ihrer herstellung und arzneipraeparate - Google Patents
5-hydroxy-2-(3-trifluormethylanilino)pyridin-3-carbonsaeure, verfahren zu ihrer herstellung und arzneipraeparateInfo
- Publication number
- DE2300322A1 DE2300322A1 DE2300322A DE2300322A DE2300322A1 DE 2300322 A1 DE2300322 A1 DE 2300322A1 DE 2300322 A DE2300322 A DE 2300322A DE 2300322 A DE2300322 A DE 2300322A DE 2300322 A1 DE2300322 A1 DE 2300322A1
- Authority
- DE
- Germany
- Prior art keywords
- hydroxy
- pyridine
- trifluoromethylanilino
- carboxylic acid
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims description 11
- -1 3-TRIFLUOROMETHYLANILINO Chemical class 0.000 title claims description 9
- 238000000034 method Methods 0.000 title claims description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 title description 3
- 238000004519 manufacturing process Methods 0.000 title description 3
- 239000011664 nicotinic acid Substances 0.000 title description 3
- 235000001968 nicotinic acid Nutrition 0.000 title description 2
- PQPZBSPGQLJEAT-UHFFFAOYSA-N 5-hydroxy-2-[3-(trifluoromethyl)anilino]pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC(O)=CN=C1NC1=CC=CC(C(F)(F)F)=C1 PQPZBSPGQLJEAT-UHFFFAOYSA-N 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 6
- OKIASDFNVMJNDT-UHFFFAOYSA-N 2-chloro-5-hydroxypyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC(O)=CN=C1Cl OKIASDFNVMJNDT-UHFFFAOYSA-N 0.000 claims description 5
- VIUDTWATMPPKEL-UHFFFAOYSA-N 3-(trifluoromethyl)aniline Chemical compound NC1=CC=CC(C(F)(F)F)=C1 VIUDTWATMPPKEL-UHFFFAOYSA-N 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 239000000463 material Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 description 10
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 6
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 4
- 229910017604 nitric acid Inorganic materials 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- OSIOIGXJUZTWRI-UHFFFAOYSA-N 2-chloro-3-methyl-5-nitropyridine Chemical compound CC1=CC([N+]([O-])=O)=CN=C1Cl OSIOIGXJUZTWRI-UHFFFAOYSA-N 0.000 description 2
- WOFZRBCITDVRON-UHFFFAOYSA-N 2-chloro-5-nitronicotinic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CN=C1Cl WOFZRBCITDVRON-UHFFFAOYSA-N 0.000 description 2
- FPTYZBDNBMVYCL-UHFFFAOYSA-N 3-methyl-5-nitro-1h-pyridin-2-one Chemical compound CC1=CC([N+]([O-])=O)=CN=C1O FPTYZBDNBMVYCL-UHFFFAOYSA-N 0.000 description 2
- RGDQRXPEZUNWHX-UHFFFAOYSA-N 3-methylpyridin-2-amine Chemical compound CC1=CC=CN=C1N RGDQRXPEZUNWHX-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000012954 diazonium Substances 0.000 description 2
- 150000001989 diazonium salts Chemical group 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940126601 medicinal product Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 235000011150 stannous chloride Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IBRSSZOHCGUTHI-UHFFFAOYSA-N 2-chloropyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1Cl IBRSSZOHCGUTHI-UHFFFAOYSA-N 0.000 description 1
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
- FHLUOUXEXWHPHZ-UHFFFAOYSA-N 3-(2,2,2-trifluoroethyl)aniline Chemical compound NC1=CC=CC(CC(F)(F)F)=C1 FHLUOUXEXWHPHZ-UHFFFAOYSA-N 0.000 description 1
- JLPYUDJJBGYXEZ-UHFFFAOYSA-N 3-methyl-5-nitropyridin-2-amine Chemical compound CC1=CC([N+]([O-])=O)=CN=C1N JLPYUDJJBGYXEZ-UHFFFAOYSA-N 0.000 description 1
- ZZLGRVWAJFJQQK-UHFFFAOYSA-N 5-amino-2-chloropyridine-3-carboxylic acid Chemical compound NC1=CN=C(Cl)C(C(O)=O)=C1 ZZLGRVWAJFJQQK-UHFFFAOYSA-N 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical class OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006193 diazotization reaction Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000002440 hydroxy compounds Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21626072A | 1972-01-07 | 1972-01-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2300322A1 true DE2300322A1 (de) | 1973-07-12 |
Family
ID=22806384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2300322A Pending DE2300322A1 (de) | 1972-01-07 | 1973-01-04 | 5-hydroxy-2-(3-trifluormethylanilino)pyridin-3-carbonsaeure, verfahren zu ihrer herstellung und arzneipraeparate |
Country Status (6)
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES392973A1 (es) * | 1971-01-07 | 1974-11-16 | Roemmers S A Ind Comercial | Procedimiento para la preparacion de derivados anilicos delacido nicotinico. |
-
1972
- 1972-12-21 CA CA159,707A patent/CA956318A/en not_active Expired
-
1973
- 1973-01-04 DE DE2300322A patent/DE2300322A1/de active Pending
- 1973-01-04 FR FR7300266A patent/FR2181652A1/fr active Granted
- 1973-01-05 CH CH11073A patent/CH561697A5/xx not_active IP Right Cessation
- 1973-01-06 HU HUSU798A patent/HU164687B/hu unknown
- 1973-01-08 JP JP48005102A patent/JPS4876876A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| FR2181652A1 (en) | 1973-12-07 |
| HU164687B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1974-03-28 |
| CA956318A (en) | 1974-10-15 |
| FR2181652B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1976-09-03 |
| JPS4876876A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1973-10-16 |
| CH561697A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1975-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2634288B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE2365526A1 (de) | Pharmazeutische zusammensetzung mit entzuendungshemmender, analgetischer, antipyretischer, hustenstillender und die geschwuerbildung hemmender wirkung | |
| DE1957722C3 (de) | Substituierte 2- [N-Aminoalkyl-N-(2,6dichlorphenyl)-amino] -imidazoline-^), deren Säureadditionssalze, Verfahren zu ihrer Herstellung und deren Verwendung | |
| DE2653257A1 (de) | Neue kondensierte pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als entzuendungshemmende und die gerinnung des blutes hemmende arzneimittel | |
| DE2118109A1 (de) | Neue chemische Verbindung | |
| EP0132811A1 (de) | In 1-Stellung substituierte 4-Hydroxymethyl-pyrrolidinone, Verfahren zu ihrer Herstellung, pharmazeutische Zusammensetzungen und Zwischenprodukte | |
| DE3445192C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE2300322A1 (de) | 5-hydroxy-2-(3-trifluormethylanilino)pyridin-3-carbonsaeure, verfahren zu ihrer herstellung und arzneipraeparate | |
| CH414658A (de) | Verfahren zur Herstellung von Riboflavin-2',3',4',5'-tetrabutyrat | |
| DE1770331A1 (de) | Verfahren zur Herstellung einer neuen heterocylischen Verbindung mit entzuendungshemmender Wirksamkeit | |
| DE2054142A1 (de) | Pyridinsulfonsauren | |
| DE2731662A1 (de) | 5-(2-furoyl)-, 5-(2-thenoyl)-, 5-(3-furoyl)- und 5-(3-thenoyl)-1,2- dihydro-3h-pyrrolo- eckige klammer auf 1,2-a eckige klammer zu -pyrrol-1-carbonsaeurederivate und verfahren zur herstellung derselben | |
| DE1518354B2 (de) | Aminophenylsalicylate, Verfahren zu deren Herstellung und Arzneimittel | |
| DE2530515C2 (de) | 4- bzw. 7-Hydroxy-4,5,6,7-tetrahydrothieno-[3,2-c] bzw.[2,3-c] pyridine, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittelzubereitungen | |
| DE2641129A1 (de) | Derivate des 5-aminomethylthiazols, ihr herstellungsverfahren und pharmazeutische zusammensetzungen | |
| DE3807595A1 (de) | Optisch aktive oxo-isoindolinyl-derivate und verfahren zu deren herstellung | |
| CH655115A5 (de) | Substituierte aethenylderivate von 1h-pyrazolo-(1,5-a)-pyrimidin und verfahren zur herstellung derselben. | |
| DE2031238C3 (de) | i.a-Diphenyl-S.S-dioxo^-substituierter Pyrazolidine, Verfahren zu deren Herstellung und Arzneimittel | |
| DE3542906C2 (de) | D-6-Methoxy-alpha-methyl-2-naphthalin-essigsaures Salz mit dem Natriumsalz von 1-Carboxy-N,N',N"-trimethylmethanamin, Verfahren zu seiner Herstellung und Arzneimittel, welches diese Verbindung enthält | |
| DE2016057C3 (de) | Eckige Klammer auf (Thenyliden (2)- amino)-oxy] -alkylcarbonsäuren, deren Salze und Alkylester, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate | |
| DE2065570C3 (de) | 2-Chlor-5-pyrrolidinoacetyl-5,10dihydro-11 H-dibenzo eckige Klammer auf b,e eckige Klammer zu eckige Klammer auf 1,4 eckige Klammer zu diazepin-11-on, ein Verfahren zu dessen Herstellung und dieses enthaltende Arzneimittel | |
| DE2607627A1 (de) | 1-0-acetoxybenzoyl-4-hydroxy-l-prolin sowie 1-0-acetoxybenzoyl-l-prolin, verfahren zu ihrer herstellung und ihre verwendung als medikament | |
| DE3447730A1 (de) | Pyrazolopyridinderivate | |
| DE2239272C3 (de) | 2-(3,4-Dichloranilino)-chinoliziniumbromid, dessen Herstellung und Arzneimittel | |
| DE2031238B2 (de) | 1,2-diphenyl-3,5-dioxo-4-substituierter pyrazolidine, verfahren zu deren herstellung und arzneimittel |